Movement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains

Market Focus06-29

On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.

On the news front, the company announced that 193 million IPO lock-up shares (34.16% of total equity) will become eligible for trading on July 1. However, due to the company's cash dividends falling short of regulatory requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing holdings via centralized bidding or block trades on A-shares, significantly alleviating actual selling pressure below market expectations.

Additionally, the company's core product Telitacicept (RC18), a first-in-class BLyS/APRIL dual-target fusion protein, recently received NMPA approval for two new indications — Sjogren's syndrome and IgA nephropathy — marking the first approved biologic for Sjogren's syndrome globally. Telitacicept now has five approved indications domestically, strengthening commercialization ramp-up expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130763370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130763370","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains","media":"Market Focus","content":"<p><p>On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.</p><p>On the news front, the company announced that 193 million IPO lock-up shares (34.16% of total equity) will become eligible for trading on July 1. However, due to the company's cash dividends falling short of regulatory requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing holdings via centralized bidding or block trades on A-shares, significantly alleviating actual selling pressure below market expectations.</p><p>Additionally, the company's core product Telitacicept (RC18), a first-in-class BLyS/APRIL dual-target fusion protein, recently received NMPA approval for two new indications — Sjogren's syndrome and IgA nephropathy — marking the first approved biologic for Sjogren's syndrome globally. Telitacicept now has five approved indications domestically, strengthening commercialization ramp-up expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.</p><p>On the news front, the company announced that 193 million IPO lock-up shares (34.16% of total equity) will become eligible for trading on July 1. However, due to the company's cash dividends falling short of regulatory requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing holdings via centralized bidding or block trades on A-shares, significantly alleviating actual selling pressure below market expectations.</p><p>Additionally, the company's core product Telitacicept (RC18), a first-in-class BLyS/APRIL dual-target fusion protein, recently received NMPA approval for two new indications — Sjogren's syndrome and IgA nephropathy — marking the first approved biologic for Sjogren's syndrome globally. Telitacicept now has five approved indications domestically, strengthening commercialization ramp-up expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1130763370","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130763370","pubTimestamp":1782697592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.On the news front, the company announced that 193 million IPO lock-up shares (34.16% of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"运动快讯|Remegen常规交易涨5.38%锁定股份限售和新药获批推动涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.On the news front, the company announced that 193 million IPO lock-up shares (34.16% of total equity) will become eligible for trading on July 1. However, due to the company's cash dividends falling short of regulatory requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing holdings via centralized bidding or block trades on A-shares, significantly alleviating actual selling pressure below market expectations.Additionally, the company's core product Telitacicept (RC18), a first-in-class BLyS/APRIL dual-target fusion protein, recently received NMPA approval for two new indications — Sjogren's syndrome and IgA nephropathy — marking the first approved biologic for Sjogren's syndrome globally. Telitacicept now has five approved indications domestically, strengthening commercialization ramp-up expectations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130763370","isCrawlerRequest":true}